Travere Therapeutics, Inc. (TVTX)
52.12
+0.08
(+0.16%)
USD |
NASDAQ |
Oct 09, 16:00
52.17
+0.04
(+0.09%)
After-Hours: 20:00
Travere Therapeutics Free Cash Flow : 15.40M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.40M |
| March 31, 2026 | -28.94M |
| December 31, 2025 | -20.37M |
| September 30, 2025 | -107.47M |
| June 30, 2025 | -157.30M |
| March 31, 2025 | -202.19M |
| December 31, 2024 | -273.69M |
| September 30, 2024 | -304.41M |
| June 30, 2024 | -317.77M |
| March 31, 2024 | -338.67M |
| December 31, 2023 | -322.28M |
| September 30, 2023 | -305.11M |
| June 30, 2023 | -288.21M |
| March 31, 2023 | -263.34M |
| December 31, 2022 | -214.85M |
| September 30, 2022 | -188.09M |
| June 30, 2022 | -114.24M |
| March 31, 2022 | -63.79M |
| December 31, 2021 | -38.94M |
| September 30, 2021 | -29.34M |
| June 30, 2021 | -56.21M |
| March 31, 2021 | -69.28M |
| December 31, 2020 | -67.31M |
| September 30, 2020 | -53.31M |
| June 30, 2020 | -71.47M |
| Date | Value |
|---|---|
| March 31, 2020 | -83.08M |
| December 31, 2019 | -73.78M |
| September 30, 2019 | -72.74M |
| June 30, 2019 | -62.14M |
| March 31, 2019 | -46.14M |
| December 31, 2018 | -44.66M |
| September 30, 2018 | -41.02M |
| June 30, 2018 | -30.82M |
| March 31, 2018 | -22.50M |
| December 31, 2017 | -6.606M |
| September 30, 2017 | -13.81M |
| June 30, 2017 | -14.31M |
| March 31, 2017 | -14.44M |
| December 31, 2016 | -13.52M |
| September 30, 2016 | -6.799M |
| June 30, 2016 | -11.21M |
| March 31, 2016 | -6.392M |
| December 31, 2015 | -7.584M |
| September 30, 2015 | -12.49M |
| June 30, 2015 | -25.69M |
| March 31, 2015 | -47.14M |
| December 31, 2014 | -49.81M |
| September 30, 2014 | -53.01M |
| June 30, 2014 | -40.02M |
| March 31, 2014 | -27.29M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| TG Therapeutics, Inc. | 17.38M |
| BioMarin Pharmaceutical, Inc. | 725.08M |
| Vertex Pharmaceuticals, Inc. | 3.796B |
| Viridian Therapeutics, Inc. | -335.52M |
| Krystal Biotech, Inc. | 257.78M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 58.07M |
| Cash from Investing (Quarterly) | -206.29M |
| Cash from Financing (Quarterly) | 187.52M |
| Free Cash Flow Per Share (Quarterly) | 0.3958 |
| Free Cash Flow to Equity (Quarterly) | -252.24M |
| Free Cash Flow to Firm (Quarterly) | 39.12M |
| Free Cash Flow Yield | 0.31% |